



## Pertti Neuvonen Symposium – Clinical Pharmacology and Therapeutics: from Research to Clinical Practice

**Biomedicum Helsinki, Lecture Hall 1 / Zoom  
29.-30.11.2021**

### Scientific program

#### Monday 29.11.2021

10.30	Opening words (20 min)
10.50-12.05	Session 1 (Chair: Janne Backman) <ul style="list-style-type: none"> <li>• Role of clinical pharmacology in improving medication safety of new oral anticancer drugs, <b>Martin Fromm</b>, University of Erlangen-Nuremberg (25+5 min)</li> <li>• The Geneva cocktail: phenotyping of drug metabolism and transport, <b>Caroline Samer</b>, University of Geneva (25+5 min)</li> <li>• Progress report: Hydroxychloroquine is metabolized by CYP2D6, CYP3A4 and CYP2C8, and inhibits CYP2D6 <i>in vitro</i>, <b>Marie-Noëlle Paludetto</b>, University of Helsinki (10+5 min)</li> </ul>
12.15-13.15	Lunch break
13.15-14.30	Session 2 (Chair: Mikko Niemi) <ul style="list-style-type: none"> <li>• Personalized Therapy and Renal Cancer, <b>Matthias Schwab</b>, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (25+5 min)</li> <li>• Novel principles for genetic analyses combined with validated in vivo like liver 3D models to provide better pre-emptive genotyping in pharmacotherapy, <b>Magnus Ingelman-Sundberg</b>, Karolinska Institutet (25+5 min)</li> <li>• Progress report: Toxicity and therapy outcome associations in <i>LIG3</i>, <i>SLCO1B3</i>, <i>ABCB1</i>, <i>OPRM1</i> and <i>GSTP1</i> in high grade serous ovarian cancer, <b>Feng Deng</b>, University of Helsinki (10+5 min)</li> </ul>
14.30-14.40	Short poster presentations: <ul style="list-style-type: none"> <li>• O-GLCNAC transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage, <b>Aishwarya Gondane</b>, University of Helsinki</li> </ul>
14.40-15.00	Coffee break
15.00-16.15	Session 3 (Chair: Outi Lapatto-Reiniluoto) <ul style="list-style-type: none"> <li>• Bayesian modeling as a clinical pharmacokinetic tool, <b>Teijo Saari</b>, University of Turku (25+5 min)</li> <li>• Innovations in precision medicine, <b>Pierre Marquet</b>, University of Limoges (25+5 min)</li> <li>• Progress report: Initiation of pharmacogenetically actionable drugs in discharged hospital patients in Finland, <b>Noora Kulla</b>, University of Turku (10+5 min)</li> </ul>

**Tuesday 30.11.2021**

9.15-9.45	Session 4 (Chair: Alekski Tornio) <ul style="list-style-type: none"><li>Individualised drug therapy - Clinical pharmacology services in health care, <b>Marja-Liisa Dahl</b>, Karolinska Institutet (25+5 min)</li></ul>
9.45-9.55	Short poster presentations: <ul style="list-style-type: none"><li>Genome-scale discovery of novel RNA polymerase II pausing regulators, <b>Rhiannon Newman</b>, University of Helsinki</li><li>Trophic factor CPX201A delays disease onset and increases survival in a SOD1-G93A mouse model of ALS, <b>Liam Beckett</b>, University of Helsinki</li></ul>
9.55-10.15	Coffee break
10.15-11.30	<ul style="list-style-type: none"><li>Isoxazolyl penicillins as inducers of drug metabolism and clinical impact, <b>Tore B Stage</b>, University of Southern Denmark (25+5 min)</li><li>Investigation of drug-drug interaction between tyrosine kinase inhibitors and warfarin based on PBPK modeling, <b>Xiaoqiang Xiang</b>, Fudan University (25+5 min)</li><li>Progress report: <i>In vitro</i> inhibitory effects and mechanisms of tyrosine kinase inhibitors on warfarin, <b>Shasha Jin</b>, Fudan University and University of Helsinki (10+5 min)</li></ul>
11.30-12.30	Lunch break
12.30-13.50	Session 5 (Chair: Katriina Tarkiainen) <ul style="list-style-type: none"><li>The Glymphatic System: Implications on CNS Pharmacotherapy, <b>Tuomas Lilius</b>, University of Helsinki and University of Copenhagen (25+5 min)</li><li>Current and future prospects in teratology research, <b>Heli Malm</b>, Helsinki University Hospital (25+5 min)</li><li>Physiologically-based pharmacokinetic simulations to individualize drug treatment, <b>Anne Filppula</b>, Åbo Akademi (15+5 min)</li></ul>
13.50-14.15	Coffee break
14.15-15.30	Session 6 (Chair: Janne Backman) <ul style="list-style-type: none"><li>Clinical pharmacology of the aging population: a toolbox for optimal deprescribing, <b>Sirpa Hartikainen</b>, University of Eastern Finland (25+5 min)</li><li>Financial toxicity in pharmacotherapy – weighing access to novel medicines, <b>Miia Turpeinen</b>, University of Oulu (25+5 min)</li><li>Progress report: Comprehensive pharmacogenomic study of simvastatin pharmacokinetics: Major role of <i>SLCO1B1</i> and <i>CYP3A4</i>, <b>Anssi Mykkänen</b>, University of Helsinki (10+5 min)</li></ul>
15.30-15.45	Closing words

